CA3203450A1 - Procede analytique pour glycoconjugues a l'aide d'un systeme de dosage immunologique a base capillaire - Google Patents
Procede analytique pour glycoconjugues a l'aide d'un systeme de dosage immunologique a base capillaire Download PDFInfo
- Publication number
- CA3203450A1 CA3203450A1 CA3203450A CA3203450A CA3203450A1 CA 3203450 A1 CA3203450 A1 CA 3203450A1 CA 3203450 A CA3203450 A CA 3203450A CA 3203450 A CA3203450 A CA 3203450A CA 3203450 A1 CA3203450 A1 CA 3203450A1
- Authority
- CA
- Canada
- Prior art keywords
- glycoconjugate
- sample
- signal
- capillary
- glycoconjugates
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004458 analytical method Methods 0.000 title claims abstract description 47
- 238000003018 immunoassay Methods 0.000 title claims description 30
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 239000000523 sample Substances 0.000 claims description 99
- 150000004676 glycans Chemical class 0.000 claims description 97
- 210000001736 capillary Anatomy 0.000 claims description 72
- 239000005017 polysaccharide Substances 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 65
- 229920001282 polysaccharide Polymers 0.000 claims description 62
- 108010078791 Carrier Proteins Proteins 0.000 claims description 60
- 102000014914 Carrier Proteins Human genes 0.000 claims description 60
- 238000012360 testing method Methods 0.000 claims description 51
- 238000011002 quantification Methods 0.000 claims description 48
- 241000588724 Escherichia coli Species 0.000 claims description 46
- 230000010354 integration Effects 0.000 claims description 34
- 150000002772 monosaccharides Chemical class 0.000 claims description 34
- 229960005486 vaccine Drugs 0.000 claims description 34
- 238000011088 calibration curve Methods 0.000 claims description 31
- 230000000875 corresponding effect Effects 0.000 claims description 27
- 239000013068 control sample Substances 0.000 claims description 19
- 239000011159 matrix material Substances 0.000 claims description 17
- 108090000623 proteins and genes Proteins 0.000 claims description 15
- 102000004169 proteins and genes Human genes 0.000 claims description 15
- 238000004590 computer program Methods 0.000 claims description 12
- 239000000758 substrate Substances 0.000 claims description 10
- 230000021615 conjugation Effects 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108010089072 Dolichyl-diphosphooligosaccharide-protein glycotransferase Proteins 0.000 claims description 6
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 238000012417 linear regression Methods 0.000 claims description 6
- 101710082714 Exotoxin A Proteins 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 230000002255 enzymatic effect Effects 0.000 claims description 5
- 239000012723 sample buffer Substances 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 3
- 239000002736 nonionic surfactant Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims 1
- 230000036647 reaction Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 description 50
- 239000000306 component Substances 0.000 description 49
- 230000013595 glycosylation Effects 0.000 description 20
- 238000006206 glycosylation reaction Methods 0.000 description 20
- 102000003886 Glycoproteins Human genes 0.000 description 17
- 108090000288 Glycoproteins Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 15
- 102000036639 antigens Human genes 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 235000018102 proteins Nutrition 0.000 description 14
- 238000005259 measurement Methods 0.000 description 12
- 238000006640 acetylation reaction Methods 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 150000004804 polysaccharides Polymers 0.000 description 9
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- -1 2'-fluororibose Chemical class 0.000 description 5
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 5
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 5
- 238000013103 analytical ultracentrifugation Methods 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 239000012925 reference material Substances 0.000 description 5
- 108091035707 Consensus sequence Proteins 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000012491 analyte Substances 0.000 description 4
- 238000007405 data analysis Methods 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 3
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 3
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 3
- 241000607768 Shigella Species 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108020001775 protein parts Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 239000012099 Alexa Fluor family Substances 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 108010004469 allophycocyanin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000005251 capillar electrophoresis Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 229930182830 galactose Natural products 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101100094968 Caenorhabditis elegans sam-10 gene Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 206010056740 Genital discharge Diseases 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- SQVRNKJHWKZAKO-PFQGKNLYSA-N N-acetyl-beta-neuraminic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)O[C@H]1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-PFQGKNLYSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GBXZONVFWYCRPT-KVTDHHQDSA-N [(2s,3s,4r,5r)-3,4,5,6-tetrahydroxy-1-oxohexan-2-yl] dihydrogen phosphate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](C=O)OP(O)(O)=O GBXZONVFWYCRPT-KVTDHHQDSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 108091006004 biotinylated proteins Proteins 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 108091008053 gene clusters Proteins 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- YELGFTGWJGBAQU-UHFFFAOYSA-N mephedrone Chemical compound CNC(C)C(=O)C1=CC=C(C)C=C1 YELGFTGWJGBAQU-UHFFFAOYSA-N 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000001048 orange dye Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 229940036310 program Drugs 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 150000008264 rhamnoses Chemical class 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- XIUROWKZWPIAIB-UHFFFAOYSA-N sulfotep Chemical compound CCOP(=S)(OCC)OP(=S)(OCC)OCC XIUROWKZWPIAIB-UHFFFAOYSA-N 0.000 description 1
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- QOFZZTBWWJNFCA-UHFFFAOYSA-N texas red-X Chemical compound [O-]S(=O)(=O)C1=CC(S(=O)(=O)NCCCCCC(=O)O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 QOFZZTBWWJNFCA-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
- G01N33/561—Immunoelectrophoresis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/24—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- G01N2333/245—Escherichia (G)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Electrochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
L'invention concerne des procédés analytiques pour identifier et quantifier des compositions de glycoconjugués complexes, en particulier pour analyser un glycoconjugué dans un échantillon comprenant au moins 4 glycoconjugués.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20210768 | 2020-11-30 | ||
EP20210768.6 | 2020-11-30 | ||
PCT/IB2021/061115 WO2022113048A1 (fr) | 2020-11-30 | 2021-11-30 | Procédé analytique pour glycoconjugués à l'aide d'un système de dosage immunologique à base capillaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3203450A1 true CA3203450A1 (fr) | 2022-06-02 |
Family
ID=73646265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3203450A Pending CA3203450A1 (fr) | 2020-11-30 | 2021-11-30 | Procede analytique pour glycoconjugues a l'aide d'un systeme de dosage immunologique a base capillaire |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230349913A1 (fr) |
EP (1) | EP4252003A1 (fr) |
JP (1) | JP7495578B2 (fr) |
CN (1) | CN116406445A (fr) |
CA (1) | CA3203450A1 (fr) |
IL (1) | IL301880A (fr) |
WO (1) | WO2022113048A1 (fr) |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5431793A (en) * | 1994-07-29 | 1995-07-11 | Beckman Instruments, Inc. | Quantitative analysis of glycosylated hemoglobin by immunocappillary electrophoresis |
CA2301942C (fr) * | 1997-08-27 | 2011-05-31 | Chiron Corporation | Mimetiques moleculaires des epitopes b meningococciques |
US6087128A (en) * | 1998-02-12 | 2000-07-11 | Ndsu Research Foundation | DNA encoding an avian E. coli iss |
US7179658B2 (en) * | 2001-09-06 | 2007-02-20 | Beckman Coulter, Inc. | Particle based homogeneous assays using capillary electrophoresis with laser-induced fluorescence detection |
FI20055417A0 (fi) * | 2005-07-20 | 2005-07-20 | Glykos Finland Oy | Syöpäpesifiset glykaanit ja niiden käyttö |
JP2007017445A (ja) * | 2006-07-20 | 2007-01-25 | Ge Healthcare Bioscience Kk | クロマトグラフィー用充填剤 |
US20090023156A1 (en) * | 2007-07-20 | 2009-01-22 | Voss Karl O | Methods and reagents for quantifying analytes |
LT2257307T (lt) | 2008-02-20 | 2018-08-10 | Glaxosmithkline Biologicals S.A. | Biokonjugatai, gauti iš rekombinantinių n-glikozilintų baltymų iš prokariotinių ląstelių |
US20180259508A1 (en) * | 2008-12-10 | 2018-09-13 | University Of Georgia Research Foundation, Inc. | Glycan-specific analytical tools |
WO2013034664A1 (fr) * | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Vaccins bioconjugués fabriqués dans des cellules procaryotes |
AU2015220723C1 (en) | 2014-02-24 | 2018-04-05 | Glaxosmithkline Biologicals Sa | Novel polysaccharide and uses thereof |
TWI715617B (zh) | 2015-08-24 | 2021-01-11 | 比利時商葛蘭素史密斯克藍生物品公司 | 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物 |
EP3410118B1 (fr) * | 2016-01-27 | 2020-09-30 | FUJIFILM Wako Pure Chemical Corporation | Procédé de détermination du cancer de la prostate |
CN107576733B (zh) * | 2017-06-26 | 2020-11-24 | 复旦大学 | 一种基于糖蛋白非糖肽的质谱多反应监测定量糖蛋白方法 |
JP2019148564A (ja) * | 2018-02-28 | 2019-09-05 | 学校法人近畿大学 | 糖鎖解析方法、糖鎖解析システム、糖鎖解析用プログラム、及び糖鎖解析用キット |
WO2019175145A1 (fr) * | 2018-03-12 | 2019-09-19 | Janssen Vaccines & Prevention B.V. | Vaccins contre des infections des voies urinaires |
WO2019221279A1 (fr) * | 2018-05-18 | 2019-11-21 | 富士フイルム和光純薬株式会社 | Procédé de détermination du carcinome de la prostate |
JP7370391B2 (ja) | 2019-03-18 | 2023-10-27 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | 大腸菌o抗原多糖のバイオコンジュゲート、その製造方法およびその使用方法 |
KR102574882B1 (ko) | 2019-03-18 | 2023-09-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 대장균 o-항원 다당류의 바이오컨쥬게이트의 생성 방법, 이의 조성물 및 이의 사용 방법 |
-
2021
- 2021-11-30 US US18/038,833 patent/US20230349913A1/en active Pending
- 2021-11-30 JP JP2023532197A patent/JP7495578B2/ja active Active
- 2021-11-30 CN CN202180075323.5A patent/CN116406445A/zh active Pending
- 2021-11-30 IL IL301880A patent/IL301880A/en unknown
- 2021-11-30 CA CA3203450A patent/CA3203450A1/fr active Pending
- 2021-11-30 EP EP21819229.2A patent/EP4252003A1/fr active Pending
- 2021-11-30 WO PCT/IB2021/061115 patent/WO2022113048A1/fr active Application Filing
Also Published As
Publication number | Publication date |
---|---|
IL301880A (en) | 2023-06-01 |
JP2023549573A (ja) | 2023-11-27 |
US20230349913A1 (en) | 2023-11-02 |
WO2022113048A1 (fr) | 2022-06-02 |
JP7495578B2 (ja) | 2024-06-04 |
EP4252003A1 (fr) | 2023-10-04 |
CN116406445A (zh) | 2023-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Safina | Application of surface plasmon resonance for the detection of carbohydrates, glycoconjugates, and measurement of the carbohydrate-specific interactions: A comparison with conventional analytical techniques. A critical review | |
JP4711190B2 (ja) | グリコシル化異常症の検査方法 | |
JP4824119B2 (ja) | 糖鎖構造プロファイリング技術 | |
Uchiyama et al. | Optimization of evanescent‐field fluorescence‐assisted lectin microarray for high‐sensitivity detection of monovalent oligosaccharides and glycoproteins | |
McQuillan et al. | Natural and synthetic sialylated glycan microarrays and their applications | |
Guo et al. | Recent advances in the analysis of polysialic acid from complex biological systems | |
Wang et al. | Multiplex profiling of glycoproteins using a novel bead‐based lectin array | |
US10684253B2 (en) | Method for automated high throughput identification of carbohydrates and carbohydrate mixture composition patterns as well as systems therefore | |
Bao et al. | Capillary electrophoresis of acidic oligosaccharides from human milk | |
Yue et al. | Microarrays in glycoproteomics research | |
KR20150062915A (ko) | 혈액 당단백질을 이용하는 암 마커 및 이를 이용하는 암 진단방법 | |
Luo et al. | Characterization and analysis of biopharmaceutical proteins | |
JP5466405B2 (ja) | ヒアルロン酸の分子量の測定方法 | |
CA3203450A1 (fr) | Procede analytique pour glycoconjugues a l'aide d'un systeme de dosage immunologique a base capillaire | |
WO2008007159B1 (fr) | Mesure des produits d'activation du complément sur des ensembles d'antigènes | |
Heegaard | Affinity Electrophoresis for the Characterization of Glycoproteins—The Use of Lectins in Combination with Immunoelectrophoresis | |
EP4143564B1 (fr) | Procédé d'identification et de quantification de polysaccharides dans des compositions de glycoconjugués complexes | |
Goodarzi et al. | A lectin method for investigating the glycosylation of nanogram amounts of purified glycoprotein | |
KR101143891B1 (ko) | 단백질의 비정상적인 당쇄화를 이용하는 암진단 마커 | |
KR101100809B1 (ko) | 암 진단용 펩티드 마커 및 이를 이용한 암 진단방법 | |
CN108333348B (zh) | 用于检测氯霉素的试纸条及其制备方法 | |
Wu et al. | A novel, sensitive and convenient method for determination of sialic acids in human serum utilizing ultrasonic-assisted closed in-syringe hydrolysis and derivatization prior to high performance liquid chromatography | |
Kilár et al. | Novel quantitative electrophoretic analysis of endotoxins on microchips | |
Bollecker et al. | Re-examination of the glycosylation of high M r Subunits of wheat glutenin | |
US20220236283A1 (en) | Method for identification and quantification of polysaccharides in complex glycoconjugate compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |
|
EEER | Examination request |
Effective date: 20230529 |